What obesity drugmakers see next in the market: More pills, easier access and drug combinations

CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare Conference in San Francisco.

Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026

Eli Lilly (NYSE: LLY) delivered a gain worthy of a technology growth stock last year. The pharma giant's shares soared 39%, which is a pretty impressive 12-month gain for a company in this industry.
pharmaphorum

Corxel's raises $287m for obesity drug, and other financings

The cash injection will also allow Corxel to start phase 2 testing in type 2 diabetes and help to fund a phase 3 programme in obesity, with some also earmarked for two other programmes – an ...

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Inogen (INGN)

According to TipRanks.com, Schock is a 2-star analyst with an average return of 2.9% and a 53.3% success rate. Schock covers the Healthcare sector, focusing on stocks such as InfuSystem Holdings, ...
Pharmaceutical Technology

Corxel raises $287m as obesity continues to spark investor interest

Corxel Pharmaceuticals has raised $287m to fund its suite of cardiometabolic assets, signifying that investor appetite for weight loss drug pipelines is showing no signs of slowing.